VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
← Pulse/Companies

Latigo Biotherapeutics on Pulse

Biotech

The full thread of our Latigo Biotherapeutics coverage — a running record of every development we've tracked, with the VC take on each.

2
Stories
1
With a headline figure
Aug 3, 2026
Since

Coverage Timeline

newest first
  1. Aug 4, 2026IPOAttovia Prices IPO as Biotech's Public Pipeline Fills Out$17/share IPO→
  2. Aug 3, 2026IPOBlue Owl-Backed Latigo Advances Nasdaq IPO Plans→

All Coverage

IPO· Aug 4, 2026

Attovia Prices IPO as Biotech's Public Pipeline Fills Out

Illustration for: Attovia Prices IPO as Biotech's Public Pipeline Fills Out
IPO$17/share IPO

Attovia Prices IPO as Biotech's Public Pipeline Fills Out

Attovia Therapeutics priced its Nasdaq IPO at $17 a share while Latigo Biotherapeutics advances its own S-1, the latest signs that the biotech listing window is filling with genuine clinical-stage pipelines.

Aug 4, 2026
IPO· Aug 3, 2026

Blue Owl-Backed Latigo Advances Nasdaq IPO Plans

Illustration for: Blue Owl-Backed Latigo Advances Nasdaq IPO Plans
IPO

Blue Owl-Backed Latigo Advances Nasdaq IPO Plans

Latigo Biotherapeutics filed an amended S-1 this week, advancing its Nasdaq IPO to fund a pivotal Phase 3 trial for its non-opioid pain drug ahead of the trial itself starting.

Aug 3, 2026
@Trace_Cohen·t@nyvp.com